#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Every­one in the can­cer R&D are­na is look­ing to build new fran­chis­es around bet­ter drugs and com­bos. And one busy pock­et of that space is cen­tered en­tire­ly on cre­at­ing an IL-2 drug that can be as ef­fec­tive as the orig­i­nal with­out the tox­i­c­i­ty that damned it to the side­lines.

Alk­er­mes $ALKS for­mal­ly tossed its hat in­to the ring of con­tenders at vir­tu­al ES­MO to­day, high­light­ing the first glimpse of ef­fi­ca­cy for their can­di­date, ALKS 4230, as both a monother­a­py as well as in com­bi­na­tion with Mer­ck’s Keytru­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER